Evaluation of treatment response after nonoperative therapy for early-stage non-small cell lung carcinoma

Cancer Journal

Volumn 17, Issue 1, 2011, Pages 38-48

  Eradat, Jilbert ^a   Abtin, Fereidoun ^a   Gutierrez, Antonio ^a   Suh, Robert ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

lung cancer; Radiofrequency ablation; radiotherapy; stereotactic body radiation therapy

Indexed keywords

CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CRYOABLATION; EARLY CANCER; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; LUNG NON SMALL CELL CANCER; MICROWAVE THERAPY; PATIENT ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; THERMAL STIMULATION; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSTIC IMAGING; HUMANS; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 79551568749     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31820a0948     Document Type: Review

References (62)

1. Cancer Facts and Figures 2010. Atlanta, GA: American Cancer Society; 2010. Available at: www.cancer.org http://www.cancer.org/9. Accessed on November 1, 2010.
2. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136:260-271.
3. Goldstraw P, Crowley J, Chansky K, et al. International Association for the Study of Lung Cancer International Staging Committee, Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706-714.
4. Ettinger DS, Akerley W, Bepler G, et al. NCCN Non-Small Cell Lung Cancer Panel Members. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: non-small cell lung cancer. J Natl Compr Cancer Netw. 2010;8:740-801.
5. Bach PB, Cramer LD, Warren JL, et al. Racial differences in the treatment of early-stage lung cancer. N Engl J Med. 1999;341:1198-1205.
6. Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest. 2003;124:1946-1955.
7. Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007;2(7 suppl 3):S94-S100.
8. Lagerwaard FJ, Haasbeek CJ, Smit EF, et al. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;70:685-692.
9. Baumann P, Nyman J, Hoyer M, et al. Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiother Oncol. 2008;88:359-367.
10. Simon CJ, Dupuy DE, DiPetrillo TA, et al. Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients. Radiology. 2007;243:268-275.
11. Lencioni R, Crocetti L, Cioni R, et al. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol. 2008;9:621-628.
12. Lanuti M, Sharma A, Digumarthy SR, et al. Radiofrequency ablation for treatment of medically inoperable stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009;137:160-166.
13. Okuma T, Matsuoka T, Yamamoto A, et al. Determinants of local progression after computed tomography-guided percutaneous radiofrequency ablation for unresectable lung tumors: 9-year experience in a single institution. Cardiovasc Intervent Radiol. 2010;33:787-793.
14. Pennathur A, Abbas G, Gooding WE, et al. Image-guided radiofrequency ablation of lung neoplasm in 100 consecutive patients by a thoracic surgical service. Ann Thorac Surg. 2009;88:1601-1606.
15. Wolf FJ, Grand DJ, Machan JT, et al. Microwave ablation of lung malignancies: effectiveness, CT findings, and safety in 50 patients. Radiology. 2008;247:871-879.
16. Kawamura M, Izumi Y, Tsukada N, et al. Percutaneous cryoablation of small pulmonary malignant tumors under computed tomographic guidance with local anesthesia for nonsurgical candidates. J Thorac Cardiovasc Surg. 2006;131:1007-1013.
17. Okuma T, Matsuoka T, Yamamoto A, et al. Assessment of early treatment response after CT-guided radiofrequency ablation of unresectable lung tumours by diffusion-weighted MRI: a pilot study. Br J Radiol. 2009;82:989-994.
18. Cosman ER, Nashold BS, Ovelman-Levitt J. Theoretical aspects of radiofrequency lesions in the dorsal root entry zone. Neurosurgery. 1984;15:945-950.
19. Organ LW. Electrophysiologic principles of radiofrequency lesion making. Appl Neurophysiol. 1976;39:69-76.
20. Haines DE, Watson DD. Tissue heating during radiofrequency catheter ablation: a thermodynamic model and observations in isolated perfused and superperfused canine right ventricular free wall. Pacing Clin Electrophysiol. 1989;12:962-976.
21. Huang S. Advances in application of radiofrequency current to catheter ablation therapy. Pacing Clin Electrophysiol. 1991;14:8-42.
22. Goldberg SN, Gazelle GS, Compton CC, et al. Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer. 2000;88:2452-2463.
23. Goldberg SN, Gazelle GS, Compton SS, et al. Radiofrequency tissue ablation in the rabbit lung: efficacy and complications. Acad Radiol. 1995;2:776-784.
24. Gandhi NS, Dupuy DE. Image-guided radiofrequency ablation as a new treatment option for patients with lung cancer. Semin Roentgenol. 2005;40:171-181.
25. Suh RD, Wallace AB, Sheehan RE, et al. Unresectable pulmonary malignancies: CT-guided percutaneous radiofrequency ablation-preliminary results. Radiology. 2003;229:821-829.
26. Gadaleta C, Mattioli V, Colucci G, et al. Radiofrequency ablation of 40 lung neoplasms: preliminary results. AJR Am J Roentgenol. 2004;183:361-368.
27. Steinke K, King J, Glenn D, et al. Radiologic appearance and complications of percutaneous computed tomography-guided radio frequencyablated pulmonary metastases from colorectal carcinoma. J Comput Assist Tomogr. 2003;27:750-757.
28. Lee JM, Jin GY, Goldberg SN, et al. Percutaneous radiofrequency ablation for inoperable non-small cell lung cancer and metastases: preliminary report. Radiology. 2004;230:125-134.
29. Yamamoto A, Nakamura K, Matsuoka T, et al. Radiofrequency ablation in a porcine lung model: correlation between CT and histopathologic findings. AJR Am J Roentgenol. 2005;185:1299-1306.
30. Anderson EM, Lees WR, Gillams AR. Early indicators of treatment success after percutaneous radiofrequency of pulmonary tumors. Cardiovasc Intervent Radiol. 2009;32:478-483.
31. Goldberg SN, Grassi CJ, Cardella JF, et al Society of Interventional Radiology Technology Assessment Committee and the International Working Group on Image-Guided Tumor Ablation. Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2009;20(7 suppl): S377-S390.
32. Okuma T, Okamura T, Matsuoka T, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for assessment of patients with unresectable recurrent or metastatic lung cancers after CT-guided radiofrequency ablation: preliminary results. Ann Nucl Med. 2006;20:115-121.
33. Bojarski JD, Dupuy DE, Mayo-Smith WW. CT imaging findings of pulmonary neoplasms after treatment with radiofrequency ablation: results in 32 tumors. AJR Am J Roentgenol. 2005;185:466-471.
34. 18F-FDG small-animal PET for monitoring the therapeutic effect of CT-guided radiofrequency ablation on implanted VX2 lung tumors in rabbits. J Nucl Med. 2006;47:1351-1358.
35. PORT Meta-analysis Trialists Group. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2005; (2): CD002142.
36. Aoki T, Nagata Y, Negoro Y, et al. Evaluation of lung injury after threedimensional conformal stereotactic radiation therapy for solitary lung tumors: CT appearance. Radiology. 2004;230:101-108.
37. Libshitz HI, Shuman LS. Radiation-induced pulmonary change: CT findings. J Comput Assist Tomogr. 1984;8:15-19.
38. Mesurolle B, Qanadli SD, Merad M, et al. Unusual radiologic findings in the thorax after radiation therapy. Radiographics. 2000;20:67-81.
39. Park KJ, Chung JY, Chun MS, et al. Radiation-induced lung disease and the impact of radiation methods on imaging features. Radiographics. 2000;20:83-98.
40. Seppenwoolde Y, Lebesque JV. Partial irradiation of the lung. Semin Radiat Oncol. 2001;11:247-258.
41. Libshitz HI, DuBrow RA, Loyer EM, et al. Radiation change in normal organs: an overview of body imaging. Eur Radiol. 1996;6:786-795.
42. Abratt RP, Morgan GW. Lung toxicity following chest irradiation in patients with lung cancer. Lung Cancer. 2002;35:103-109.
43. Cox JD, Azarnia N, Byhardt RW, et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol. 1990;8:1543-1555.
44. Rubins J, Unger M, Colice GL; American College of Chest Physicians. Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). Chest. 2007;132(3 suppl): 355S-367S.
45. Follow-up of non-small cell lung cancer. American College of Radiology. ACR Appropriateness Criteria. Available at: www.acr.org. Accessed on November 15, 2010.
46. Pagani JJ, Libshitz HI. CT manifestations of radiation-induced change in chest tissue. J Comput Assist Tomogr. 1982;6:243-248.
47. Ikezoe J, Morimoto S, Takashima S, et al. Acute radiation-induced pulmonary injury: computed tomography evaluation. Semin Ultrasound CT MR. 1990;11:409-416.
48. Fennessy JJ. Irradiation damage to the lung. J Thorac Imaging. 1987;2:68-79.
49. Bourgouin P, Cousineau G, Lemire P, et al. Differentiation of radiationinduced fibrosis from recurrent pulmonary neoplasm by CT. Can Assoc Radiol J. 1987;38:23-26.
50. Trovo M, Linda A, El Naqa I, et al. Early and late lung radiographic injury following stereotactic body radiation therapy (SBRT). Lung Cancer. 2010;69:77-85.
51. Tann M, Yeh E, Hoopes D, et al. FDG PET/CT as predictor of recurrence in a post-radiated patient with lung cancer. J Nucl Med. 2007;48(suppl 2):86P.
52. Libshitz HI, Sheppard DG. Filling in of radiation therapy-induced bronchiectatic change: a reliable sign of locally recurrent lung cancer. Radiology. 1999;210:25-27.
53. Patz EF Jr, Lowe VJ, Hoffman JM, et al. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. Radiology. 1994;191:379-382.
54. Charles HC, Baker ME, Hathorn JW, et al. Differentiation of radiation fibrosis from recurrent neoplasm: a role for 31P MR spectroscopy? AJR Am J Roentgenol. 1990;154:67-68.
55. Shioya S, Haida M, Ono Y, et al. Lung cancer: differentiation of tumor, necrosis, and atelectasis by means of T1 and T2 values measured in vitro. Radiology. 1988;167:105-109.
56. Werthmuller WC, Schiebler ML, Whaley RA, et al. Gadolinium-DTPA enhancement of lung radiation fibrosis. J Comput Assist Tomogr. 1989;13:946-948.
57. Ikezoe J, Takashima S, Morimoto S, et al. CT appearance of acute radiation-induced injury in the lung. AJR Am J Roentgenol. 1988;150:765-770.
58. Koenig TR, Munden RF, Erasmus JJ, et al. Radiation injury of the lung after three-dimensional conformal radiation therapy. AJR Am J Roentgenol. 2002;178:1383-1388.
59. Matsuo Y, Nagata Y, Mizowaki T, et al. Evaluation of mass-like consolidation after stereotactic body radiation therapy for lung tumors [published online ahead of print October 22, 2007]. Int J Clin Oncol. 2007;12:356-362.
60. Kato S, Nambu A, Onishi H, et al. Computed tomography appearances of local recurrence after stereotactic body radiation therapy for stage I non-small-cell lung carcinoma. Jpn J Radiol. 2010;28:259-265.
61. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773-1782.
62. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996;23:1409-1415.